NASDAQ:AMLX Amylyx Pharmaceuticals Q3 2026 Earnings Date & Estimates $27.20 -0.23 (-0.84%) Closing price 04:00 PM EasternExtended Trading$27.20 0.00 (0.00%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Amylyx Pharmaceuticals is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Amylyx Pharmaceuticals in Q3 2026Amylyx Pharmaceuticals is expected to post earnings of -$0.38 per share on revenue of $0.06 million. In the same quarter a year earlier Amylyx Pharmaceuticals reported -$0.37 per share. Amylyx Pharmaceuticals last reported on August 6, 2026, posting -$0.39 per share and missing the -$0.36 consensus estimate. Amylyx Pharmaceuticals has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.38Expected Revenue$0.06 millionPrior-Year EPS-$0.37Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.39 (Missed by -$0.03)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Amylyx Pharmaceuticals Q3 2026 Earnings FAQ When does Amylyx Pharmaceuticals report Q3 2026 earnings? Amylyx Pharmaceuticals (NASDAQ:AMLX) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. What time is Amylyx Pharmaceuticals' Q3 2026 earnings call? Amylyx Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Amylyx Pharmaceuticals? Analysts expect Amylyx Pharmaceuticals to post earnings of -$0.38 per share for Q3 2026. How much revenue is Amylyx Pharmaceuticals expected to report? The consensus revenue estimate for Amylyx Pharmaceuticals is $0.06 million for Q3 2026. Amylyx Pharmaceuticals Earnings HeadlinesAmylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingOctober 6 at 12:50 PM | marketscreener.comMAnalysts Offer Insights on Healthcare Companies: Cooper Co (COO), Amylyx Pharmaceuticals Inc (AMLX) and CervoMed (CRVO)October 2, 2026 | theglobeandmail.comChina ATTACK on American Dollar set for 11/12/2026A former Wall Street Journal personal finance expert warns China may be setting the stage for a major move against the US dollar, with a possible flashpoint on November 12, 2026. He lays out five steps he believes every American should consider taking before that date arrives.October 8 at 1:00 AM | International Living (Ad)Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of "Buy" from AnalystsOctober 2, 2026 | americanbankingnews.comAmylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic ForumSeptember 23, 2026 | marketscreener.comMAmylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 16, 2026 | seekingalpha.comSee More Amylyx Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amylyx Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amylyx Pharmaceuticals and other key companies, straight to your email. Email Address About Amylyx PharmaceuticalsAmylyx Pharmaceuticals (NASDAQ:AMLX) is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company is advancing a pipeline of investigational therapies across endocrine conditions and neurodegenerative diseases, including avexitide for post-bariatric hypoglycemia, AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis, and AMX0318 for post-bariatric hypoglycemia and other rare diseases. Founded in 2013 by Joshua Cohen and Justin Klee, Amylyx is headquartered in Cambridge, Massachusetts. Cohen and Klee have served as the company’s co-chief executive officers and have led its efforts to advance therapies for diseases with high unmet needs.View Amylyx Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
